FATE
FATE THERAPEUTICS INC
$1.98
-10.41%
$257.6M
No data for this timeframe.
Vol
Market Cap$257.6M
Cap SizeMicro Cap
Analyst ConsensusBuy (61%)
Inst. Holders8 funds
Inst. Value$14.8M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 2S
Insider Net $-$102.6K
Reddit Sentiment33° Cool
SEC Reports3
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001434316·Prev Close $2.21
Recent Activity
Jun 4, 2026
SEC
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli
8-K — Impact 4/10
Jun 2, 2026
activist
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: F
Jun 1, 2026
Press
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid
Impact 6/10
May 20, 2026
Insider
Valamehr Bahram sold 28,946 shares
President and CEO @ $1.88 ($54.5K)
May 20, 2026
Insider
TAHL CINDY sold 25,590 shares
See Remarks @ $1.88 ($48.1K)
May 13, 2026
SEC
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in
8-K — Impact 5/10
May 6, 2026
Insider
TAHL CINDY sold 122,220 shares
See Remarks @ $1.32 ($161.3K)
Apr 24, 2026
SEC
FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election
DEFA14A — Impact 3/10
Price Targets
$5.41
+173.3% upside
Strong Buy
Current $1.98
Low $2.20
Median $6.00
High $8.00
9 analysts
$2.20
$8.00
Analyst Ratings
5Strong Buy
6Buy
7Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 ▲ +9.6% | $-0.28 — $-0.22 | 11% YoY | 8 |
| Next Q | $-0.26 ▲ +11.8% | $-0.31 — $-0.17 | 3% YoY | 8 |
| Current FY | $-1.04 ▲ +9.1% | $-1.21 — $-0.77 | 9% YoY | 9 |
| Next FY | $-0.92 ▲ +11.9% | $-1.37 — $-0.59 | 11% YoY | 8 |
Latest Reports
NEUTRAL
8-K
4/10
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli
Jun 4, 2026
BULLISH
Press
6/10
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid
Jun 1, 2026
NEUTRAL
8-K
5/10
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $2.3M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.7M | ADD |
| MORGAN STANLEY | $901.0K | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $771.0K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Valamehr Bahram | SELL | $54.5K |
| May 20, 2026 | TAHL CINDY | SELL | $48.1K |
| May 6, 2026 | TAHL CINDY | M | $161.3K |
| May 6, 2026 | TAHL CINDY | M | $0.00 |
| May 5, 2026 | EPSTEIN ROBERT | M | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
8 institutional holders with $14.8M total value (15,104,012 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,971,347 | $8.8M | 59.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 2,360,881 | $2.3M | 15.6% | ADD +87.0% |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,734,064 | $1.7M | 11.5% | ADD +92.5% |
| 4 | MORGAN STANLEY | 916,946 | $901.0K | 6.1% | TRIM -61.8% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 784,628 | $771.0K | 5.2% | NEW |
| 6 | WELLS FARGO & COMPANY/MN | 172,283 | $169.3K | 1.1% | ADD +28.7% |
| 7 | BANK OF AMERICA CORP /DE/ | 151,107 | $148.4K | 1.0% | TRIM -68.6% |
| 8 | FMR LLC | 12,756 | $12.5K | 0.1% | TRIM -69.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,262,515 | 2,360,881 | +87.0% | $2.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 900,757 | 1,734,064 | +92.5% | $1.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 133,839 | 172,283 | +28.7% | $169.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 214,463 | 1,262,515 | +488.7% | $1.6M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 2,433,575 | 929,944 | -61.8% | $1.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 228,405 | 900,757 | +294.4% | $1.1M | 2025-Q3 |
| UBS Group AG | TRIM | 962,672 | 314,759 | -67.3% | $396.6K | 2025-Q3 |
| FMR LLC | TRIM | 34,063 | 10,484 | -69.2% | $13.2K | 2025-Q3 |
| UBS Group AG | TRIM | 1,551,081 | 962,672 | -37.9% | $1.1M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 214,463 | — | $240.2K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 388,443 | 122,130 | -68.6% | $136.8K | 2025-Q2 |
| FMR LLC | TRIM | 57,897 | 34,063 | -41.2% | $38.2K | 2025-Q2 |
| UBS Group AG | ADD | 1,103,393 | 1,551,081 | +40.6% | $1.2M | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 356,964 | 57,897 | -83.8% | $45.7K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 378,619 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 404,279 | 1,103,393 | +172.9% | $1.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 59,111 | 92,395 | +56.3% | $152.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 763,808 | — | $2.7M | 2024-Q3 |
5 unique insiders with 2 transactions. Net insider value: -$102.6K ($0.00 bought, $102.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Valamehr Bahram | President and CEO | SELL | 28,946 | $1.88 | $54.5K |
| May 20, 2026 | TAHL CINDY | See Remarks | SELL | 25,590 | $1.88 | $48.1K |
| May 6, 2026 | TAHL CINDY | See Remarks | M | 122,220 | $1.32 | $161.3K |
| May 6, 2026 | TAHL CINDY | See Remarks | M | 122,220 | $0.00 | $0.00 |
| May 5, 2026 | EPSTEIN ROBERT S | Director | M | 25,000 | $0.00 | $0.00 |
| May 5, 2026 | RASTETTER WILLIAM H | Director | M | 25,000 | $1.69 | $42.3K |
| May 5, 2026 | RASTETTER WILLIAM H | Director | M | 25,000 | $0.00 | $0.00 |
| May 5, 2026 | EPSTEIN ROBERT S | Director | M | 25,000 | $1.69 | $42.3K |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 266,280 | $0.00 | $0.00 |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 8,977,624 | $0.00 | $0.00 |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 3,691,324 | $0.00 | $0.00 |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 266,280 | $0.00 | $0.00 |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 162,013 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
4/10
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2
Jun 4, 2026
NEUTRAL
8-K
5/10
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower tha
May 13, 2026
NEUTRAL
DEFA14A
3/10
FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, pr
Apr 24, 2026
Current analyst consensus: Buy (61% buy). Based on 18 analysts: 5 strong buy, 6 buy, 7 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.41 mean target
+173.3% upside
Strong Buy (2.08)
$2.20 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.98 |
| Target Low | $2.20 |
| Target Mean | $5.41 |
| Target Median | $6.00 |
| Target High | $8.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (2.08) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.28 | $-0.22 | 11.2% | +9.6% | 4↑ 0↓ | $0.0B | -50.5% | 8 |
| Next Q 2026-09-30 |
$-0.26 | $-0.31 | $-0.17 | 2.8% | +11.8% | 5↑ 0↓ | $0.0B | -41.8% | 8 |
| Current FY 2026-12-31 |
$-1.04 | $-1.21 | $-0.77 | 9.5% | +9.1% | 6↑ 0↓ | $0.0B | -34.9% | 9 |
| Next FY 2027-12-31 |
$-0.92 | $-1.37 | $-0.59 | 11.3% | +11.9% | 3↑ 1↓ | $0.0B | 21.9% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.258 | |
| 7d ago | $-0.258 | |
| 30d ago | $-0.285 | +0.027 |
| 60d ago | $-0.285 | +0.027 |
| 90d ago | $-0.284 | +0.026 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| May 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Apr 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Mar 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Feb 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Jan 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Jun 2, 2026
activist
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company d
Jun 2, 2026
short_volume
Short Volume: FATE — 65.6% short (1.2M / 1.8M)
Short: 1,161,056 | Exempt: 115,578 | TRF Vol: 1,768,736 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
fda
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
<p align="center"><em>FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal
Jun 1, 2026
short_volume
Short Volume: FATE — 62.2% short (2.7M / 4.3M)
Short: 2,703,238 | Exempt: 309,396 | TRF Vol: 4,346,329 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
routine
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
<p>SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bring
May 13, 2026
earnings
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
<p align="center"><em>RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe system
May 11, 2026
fda
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
<p align="center"><em>Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE
May 6, 2026
earnings_calendar
FATE Q1 2026 Earnings Scheduled — 2026-05-06
May 1, 2026
other
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
<p>SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bring
Apr 30, 2026
other
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
<p>SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bri
Apr 10, 2026
short_volume
Short Volume: FATE — 75.6% short (0.4M / 0.6M)
Short: 442,749 | Exempt: 0 | TRF Vol: 585,581 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: FATE — 55.0% short (0.5M / 0.8M)
Short: 452,418 | Exempt: 0 | TRF Vol: 822,331 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
other
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company
Mar 4, 2026
other
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company
Mar 3, 2026
other
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
<p>SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bri